The US Food and Drug Administration (FDA) has authorised Novavax’s Covid-19 vaccine for emergency use in adults.
Novavax’s vaccine will be available as two-dose primary series for people aged 18 and above. The FDA’s independent Vaccines and Related Biological Products Advisory Committee voted in favour of authorization of the vaccine on June 7, saying that the benefits of the vaccine outweigh its risks for adults.
It is also being used in 170 other countries. The shots cannot be administered until the US Centres for Disease Control and Prevention’s independent vaccine advisers weigh in on whether to recommend the vaccine and the CDC director has signed off on the recommendation. The CDC’s Advisory Committee on Immunisation Practices is scheduled to meet on July 19.
Like more familiar vaccines such as hepatitis B and pertussis, the Covid-19 vaccine is protein-based, using harmless protein fragments of the virus to teach the immune system how to spot the virus and fight it off.
The vaccine was created out of a genetic sequence of the first strain of the coronavirus, the report said.
Unlike some other Covid shots, Novavax’s vaccine can be stored in standard refrigeration.
Late-stage trials found that the efficacy of the vaccine against the mild, moderate, and severe diseases is 90.4 percent, according to the company. There is not sufficient evidence to evaluate the impact of the vaccine on the transmission of the virus.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the dependability, trustworthiness, reliability, and data of the text. Raavi Media managementythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
